Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Atypical inflammatory bowel disease and multi-system inflammation expand the phenotype of inhibitor of nuclear factor kappa B kinase subunit beta gain-of-function variants.

Created on 19 Nov 2026

Authors

James J Ashton, Mercedes Selby, Zachary Green, Lynn K Win, Fernando Vázquez López, Alex Z Kadhim, Iman Nazari, Guo Cheng, Bhumita Vadgama, Anthony P Williams, Alexander Ross, R Mark Beattie, Kimberly Gilmour, Sarah Ennis

Published in

Journal of pediatric gastroenterology and nutrition. Nov 18, 2026. Epub Nov 18, 2026.

Abstract

Gain-of-function (GoF) variants in the inhibitor of nuclear factor kappa-B kinase subunit beta (IKK2) protein, encoded by inhibitor of nuclear factor kappa B kinase subunit beta (IKBKB), have previously been reported to cause autoinflammation with a progressive immunodeficiency. Genetic defects have not previously been described in inflammatory bowel disease (IBD), although disruption of highly interacting proteins, such as IKBKG and RELA, are known causes of monogenic IBD.
Using whole exome sequencing data, we screened a cohort of over 1250 adult and paediatric onset patients with IBD for deleterious variants (minor allele frequency < 0.0005, Combined Annotation Dependent Depletion [CADD] > 15) in IKBKB. We retrieved in-depth phenotypic data and performed peripheral blood mononuclear cell CD25/CD70 stimulation validation in patients with apparent IKBKB GoF variants.
We identified 11 patients with potentially pathogenic variants. Correlation with clinical and immunophenotypic data prioritised a rare, potential gain-of-function, variant in a patient and his affected parent, c.522T>G, p Asp174Glu. The proband had multi-system inflammation and severe atypical inflammatory bowel disease with rectal stricturing. We demonstrated impaired CD25/CD70 T- and B-cell responses in the patient, characteristic of the IKBKB defect, alongside hallmark immunological manifestations of reduced natural killer and B-cell numbers, and perturbed immunoglobulin titres. Treatment with a selective Janus kinase (JAK1)-inhibitor resulted in rapid clinical and biochemical improvement.
This study expands the phenotypic manifestation of IKBKB GoF variants to include IBD and demonstrates a biologically plausible targeted treatment. Further functional work is required to elucidate the precise mechanism of bowel inflammation and identify additional patients.

PMID:
43053635
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement